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SUMMARY. Chaga’s disease is an important communicable neglected disease that is gaining wider attention
due to its increasing incidence worldwide. Achalasia due to chagasic megaesophagus (CM), a complication of this
disease, is a known—yet, poorly understood—etiological factor for esophageal squamous cell carcinoma (ESCC)
development. In this study, we aimed to perform the analysis of TP53 mutations in a series of Brazilian patients
with ESCC that developed in the context CM (ESCC/CM), and to compare with the TP53 mutation profile of
patients with benign CM and patients with nonchagasic ESCC. Additionally, we intended to correlate the TP53
mutation results with patient’s clinical pathological features. By polymerase chain reaction (PCR) followed by direct
sequencing of the hotspot regions ofTP53 (exon 5 to 8), we found thatTP53mutations were present in 40.6% (13/32)
of the ESCC/CM group, 45% (18/40) of the nonchagasic ESCC group, and in only 3% (1/33) of the benign CM
group. Missense mutations were the most common in the three groups, yet, the type and mutated exon mutation
varied significantly among the groups. Clinically, the groups exhibited distinct features, with both cancer groups
(ESCC and ESCC/CM) been significantly associated higher consumption of alcohol and tobacco, older age, worse
Karnofsky performance status, poor outcome than the patients with benign CM. No significant association was
found between TP53 mutation profile and clinical–pathological features in any of the three groups. We describe
first the time the analysis of TP53 mutations in ESCC that developed in the context of CM, and the observed high
frequency of mutations, suggest thatTP53 also plays an important role in the tumorigenic process of this unexplored
etiological condition.
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from the Brazilian National Cancer Institute (INCA)
for 2016, esophageal cancer appears as the 10th most
common cause of cancer, with an estimated 10,810
new cases for the year 2016.2
Esophageal cancer has two main histological types:
esophageal squamous cell carcinoma (ESCC) and
esophageal adenocarcinoma (EADC).3 These two his-
tological types differ in both incidence trends and
etiological factors. ESCC is the most frequent his-
tological subtype in less developed countries, being
tobacco use and alcohol consumption, followed
by drinking hot beverage and nutritional deficien-
cies, the major risk factors.1,3–5 In contrast, EADC
represents up to 50% of esophageal cancer cases
in Western countries and its incidence has been
rapidly increasing, mostly explained by increasing in
prevalence of obesity and other lifestyle-associated
factors.1,3 In Brazil, ESCC is the most frequent
histological subtype, due to the abovementioned etio-
logical agents.6,7 Interestingly, in the southeast region
of Brazil, the high prevalence of megaesophagus
and achalasia due to Chagas disease has been also
described as another predisposition factor for ESCC
development.8–10
Achalasia is an esophageal motility disorder char-
acterized by aperistalsis of the esophageal body
and failure of lower esophageal sphincter relaxation,
which lead to esophageal dilatation ormegaesophagus
and progressive dysphagia in affected patients.11 The
pathogenesis of achalasia is poorly understood and
Chagas disease is the only proven etiological factor for
achalasia.12–14
Chagas disease, which is triggered by Trypanosoma
cruzi infection, affects approximately 16 million
people in Latin America and Caribbean.15 Today,
Chagas disease also affects other nonendemic regions
of the world, due to migration, with several infected
cases notified in countries such as Spain, the United
States, Canada, Australia, and Japan.15 It is estimated
that in Brazil, between 3 and 4 million people are
infected, with some endemic regions, mainly in rural
areas with 3,6 deaths per 100.000 inhabitants/year in
the last 30 years.16,17
The initial association of megaesophagus with
ESCC risk factor was reported by Fagge in the
XIX century.18 Following this observation, several
studies showed that patients with megaesophagus
exhibited an increasing risk of 3.9%–10% of ESCC
development, when compared to the normal pop-
ulation.8,19,20 The pathophysiological mechanism of
development of ESCC in patients with CM is poorly
understood. It is believed to be due the parasitic
destruction of neurons intramural myenteric, which
leads to hypertrophy of the smooth muscle cells and
increased connective tissue and thickening of the
esophagus wall (megaesophagus), with consequent
food stasis and inflammation, acanthosis, hyperker-
atosis, and leucoplakia, some of them considered as
probably premalignant conditions for ESCC.8,19–21
The studies evaluating the molecular mechanisms
underlying this carcinogenic process are scarce.22
TP53 tumor suppressor gene exhibited a major
role in the tumorigenesis of ESCC.23 TP53 is, by far,
the highest mutated gene, with frequencies varying
between studies and population, and recently, whole
genome sequencing analysis, confirm the high fre-
quency (≈60%) of TP53 mutations.24 In Brazil, it is
been reported that approximately 35%ofESCCexhib-
ited TP53 mutations.25
In the present study, we aimed to interrogate the
TP53 mutation status in a series of ESCC that
develops in patients with chagasic megaesophagus
(CM). We further intended to compare with the TP53
mutation profile of patients with benign CM and with
patients with nonchagasic ESCC. Furthermore, we
will correlate the TP53mutation profile with patient’s
clinical pathological features.
MATERIALS ANDMETHODS
Study population
In this retrospective study, we analyzed 126 patients
treated between 1990 and 2012 at three Brazilian
hospitals from the southeast of Brazil: Hospital de
Caˆncer de Barretos, Barretos, Sa˜o Paulo State; Uni-
versidade Estadual Paulista (UNESP), Botucatu, Sa˜o
Paulo State; and Universidade Federal do Triaˆngulo
Mineiro (UFTM), Uberaba, Minas Gerais State.
A comprehensive clinical-pathological questioner,
including risk factors for esophageal cancer, Chagas
serology of all patients was performed and data were
retrospectively collected from medical records of the
respective hospitals medical.
Of the 126 patients, we were not able to per-
form the TP53 mutation analysis in 21 patients,
due to absence of available tumor tissue or poor
quality of the obtained DNA. The remaining 105
patients were divided in three groups: (i) 32 patients
with ESCC associated with chagasic megaesoph-
agus confirmed by histopathologic and radiologic
reports, and positive serology for Chagas disease
(denominated ESCC/CM); (ii) 33 patients with radi-
ological and histopathological confirmation of cha-
gasic megaesophagus without ESCC (benign chagasic
megaesophagus) and positive serology for Chagas
disease (denominated CM); and (iii) 40 patients
with ESCC without the presence of chagasic megae-
sophagus and negative serology for Chagas dis-
ease (denominated ESCC). Patients previously treated
with chemotherapy or radiotherapy and without
Chagas serology or tomography were not included in
the study. This study was approved by the local ethic
committees (409/2010).
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Table 1 The clinical-pathological features of the three groups of patients
Groups (N = 105 cases)
ESCC CM ESCC/CM
Variable Category (N = 40) (N = 33) (N = 32) P-value
Male 33 (82.5%) 29 (87.9%) 28 (87.5%)Gender 0.828∗Female 7 (17.5%) 4 (12.1%) 4 (12.5%)
Mean (SD) 57.63 (9.2) 43.43 (12.3) 60.16 (10.6)Age (years) <0.001∗∗Min–max 36–75 24–60 37–76
>70 38 (95%) 33 (100.0%) 22 (73.3%)Karnofsky 0.001∗≤70 2 (5%) 0 (0.0%) 8 (26.7%)
Never 6 (15.8%) 17 (51.5%) 7 (24.1%)Tobacco 0.003∗∗∗Ever 32 (84.2%) 16 (48.5%) 22 (75.9%)
Never 10 (26.3%) 23 (69.7%) 6 (20.7%)Alcoholism <0.001∗∗∗Ever 28 (73.7%) 10 (30.3%) 23 (79.3%)
Grade I and II NA 4 (12.1%) 6 (27.3%)Megaesophagus 0.175∗Grade III and IV NA 29 (87.9%) 16 (72.7%)
Grade I 3 (20.0%) NA 3 (33.3%)
Differentiation Grade II 10 (66.7%) NA 5 (55.6%) 0.828∗
Grade III 2 (13.3%) NA 1 (11.1%)
I and II 15 (37.5%) NA 7 (23.3%)TNM staging 0.299∗∗∗III and IV 25 (62.5%) NA 23 (76.7%)
Alive without disease 9 (22.5%) 27 (81.8%) 2 (6.7%)
Alive with disease 14 (35.0%) 0 (0.0%) 9 (30.0%)Current status <0.001∗∗∗Death by disease 16 (40.0%) 0 (0.0%) 19 (63.3%)
Death by other causes 1 (2.5%) 6 (18.2%) 0 (0.0%)
∗Fisher’s exact test.
∗∗Analysis of variance.
∗∗∗Chi-square test.
CM, chagasic megaesophagus; ESCC, squamous cell carcinoma of the esophagus; ESCC/CM, squamous cell carcinoma of the esophagus
associated with chagasic megaesophagus; N, number of cases, NA, not applicable; SD, standard deviation.
DNA isolation
Formalin-fixed paraffin-embedded (FFPE) tumors
and tissue representative of the lesions were retrieved
from the Department of Pathology of the respec-
tive hospitals, and all cases were histopathologi-
cally reclassified. DNA was obtained from FFEP
sections as previously described, with some modi-
fications.26 Briefly, serially 10 μm thick unstained
sections of paraffin blocks were sectioned, with one
H&E section for identification and selection of the
selected portion (ESCC/CM—tumor tissue; CM—
megaesophagus tissue; and ESCC—tumor tissue).
Selected areas were macrodissected into a microfuge
tube using a sterile needle (Neolus, 25 G –0.5 mm).
The macrodissected tissue was deparaffinized by a
serial extraction with xylol and ethanol (100%–70%–
50%) and allowed to air dry. DNAwas extracted using
Qiagen’s QIAamp DNA Micro Kit following man-
ufacture instructions and quantified by NanoDrop R©
2000 (Thermo Scientific). DNA samples were stored
at −20◦C until further genetic analysis.
TP53 mutation analysis
Analysis of hotspot mutations of TP53 (exons 5 to 8)
was performed by polymerase chain reaction (PCR)
followed by direct sequencing, as previously described
by our group with some modifications.27 The PCR
reaction was carried out in a total volume of 15 μL,
comprising 1 μL of DNA, 1× buffer solution, 2 mM
MgCl2, 200 μM of each dNTPs, 0.3 μM of each
primer (sense and antisense) and 0.5 U Taq DNA
polymerase (Invitrogen). The primers sequenced used
were previously described.27 The PCR reaction was
performed in a Veriti 96-Wll Thermal Cycler with an
initial denaturation at 95 ◦C for 10 min, amplified
for 40 cycles of denaturation at 95 ◦C for 45 seconds,
annealing at 56 ◦C (exons 6 and 8) 57 ◦C (exon 5 and
7) for 45 seconds, extension at 72 ◦C for 45 seconds
and a final extension at 72 ◦C for 10 minutes. The
PCR products were applied in 2.0% agarose gel with
GelRed (Biotium).
The PCR product was then submitted to direct
sequencing using an ABI PRISM BigDye Termi-
nator Cycle Sequencing Ready Reaction Kit and
analyzed an Genetic Analyzer ABI PRISM 3500
(Applied Biosystems). The chromatograms were com-
pared to a TP53 reference sequence (Ensembl—
ENSG00000141510). All samples that present any
alterations were confirmed with at least two new PCR
amplifications and sequencing.
Statistical analysis
All statistical analyses were performed using the
SPSS software (Statistical Package for Social Science,
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Table 2 TP53 mutation profile in the three groups of patients
DNA Mutation Amino acid Nature of
Groups ID Exon Codon Mutation type change mutation
2 8 273 CGT→CTT G:C→T:A (CpG) Arg→Leu Missense
3 8 282 CGG→TGG G:C→A:T (CpG) Arg→Trp Missense
7 6 196 CGA→TGA G:C→A:T (CpG) Arg→Stop Nonsense
9 5 151 CCC→TCC G:C→A:T Pro→Ser Missense
11 6 220 TAT→TGT A:T→G:C Tyr→Cys Missense
14 5 151 CCC→CAC G:C→T:A Pro→His Missense
16 8 285 GAG→AAG G:C→A:T Glu→Lys Missense
17 8 275 TGT→TTT G:C→T:A Cys→Phe Missense
18 8 275 TGT→TTT G:C→T:A Cys→Phe MissenseESCC 22 8 275 TGT→TTT G:C→T:A Cys→Phe Missense
24 8 273 CGT→TGT G:C→A:T (CpG) Arg→Cys Missense
26 8 286 GAA→GTA A:T→T:A Glu→Val Missense
27 8 280 AGA→AGC A:T→C:G Arg→Ser Missense
32 8 298 GAG→TAG G:C→T:A Glu→Stop Nonsense
34 7 248 CGG→CAG G:C→A:T (CpG) Arg→Gln Missense
37 5 179 CAT→TAT G:C→A:T His→Tyr Missense
38 7 248 CGG→TGG G:C→A:T (CpG) Arg→Trp Missense
43 5 167 Del 1bp Del Gln→NA Frameshift
CM 74 6 204 GAG→AAG G:C→A:T Glu→Lys Missense
40 8 282 CGG→TGG G:C→A:T (CpG) Arg→Trp Missense
108 7 250 CCC→CTC C:G→T:A Pro→Leu Missense
114 5 141 TGC→TAC G:C→T:A Cys→Tyr Missense
120 6 196 Del 1 bp Del Arg→NA Frameshift
121 5 145 CTG→CAG A:T→T:A Leu→Glu Missense
122 6 195 ATC→TTC A:T→T:A Ile→Phe Missense
123 5 157 GTC→TTC G:C→T:A Val→Phe Missense
ESCC/CM 124 8 306 CGA→TGA G:C→A:T (CpG) Arg→Stop Nonsense
125 6 214 Del 2 bp Del His→NA Frameshift
128 8 272 GTG→GAG A:T→T:A Val→Glu Missense
129 5 132 AAG→AGG A:T→G:C Lys→Arg Missense
8 267 Del 1 bp Del Arg→NA Frameshift
130 5 172 GTT→TTT G:C→T:A Val→Phe Missense
8 285 GAG→TAG G:C→T:A Glu→Stop Nonsense
136 7 237 ATG→AAG A:T→T:A Met→Lys Missense
A, adenine; bp, base pairs, C, cytosine; CM, chagasic megaesophagus; CpG, CpG dinucleotide; Del, deletion; ESCC, squamous cell carci-
noma of the esophagus; ESCC/CM, squamous cell carcinoma of the esophagus associated with chagasic megaesophagus; G, guanine; NA,
not applicable; T, thymine.
v19.0). The characterization of the study population,
including the results clinical-pathological, follow-up
and molecular data were performed using descriptive
statistics (for continuous variables: mean and stan-
dard deviation; for categorical variables: frequencies
and percentages), presented in the form of tables. The
associations of qualitative variables were performed
using tests of association by the chi-square or Fisher’s
exact test. In the analysis of quantitative variables
were used analysis of variance (when comparing three
groups) and Student’s t test (when comparing 2 inde-
pendent groups), assuming a significance level of 5%.
Overall survival of the three groups of patients was
calculated employing the product limit estimator of
the Kaplan–Meier method using the log-rank test to
compare survival curves.
RESULTS
The major clinical-pathological features of the three
groups of patients are summarized on Table 1. Some
characteristics were significantly different between all
groups: patients with ESCC/CM and ESCC are older,
exhibited a worse Karnofsky performance status, and
showed a poor outcome than the patients with only
CM (Table 1). We also observed a significant higher
consumption of alcohol and tobacco in both cancer
groups (ESCC and ESCC/CM), than in CM patients
without cancer (Table 1).
Molecularly, the presence of nonsynonymous
(silent mutations excluded) TP53 mutations was
observed in 32 patients (Table 2 and Fig. 1). We found
TP53 mutations in 13/32 (40.6%) ESCC/CM patients
and in 18/40 (45%) ESCC patients. In the ESCC/CM
group, two patients (ID129 and ID130) exhibited
two distinct mutations (Table 2). Only one (3%, 1/33)
CM patient showed the presence of TP53 mutation
(Table 2).
The TP53 mutation frequency was statistically sig-
nificantly different between the three groups (P <
0.001) (Table 3), mainly due to the low prevalence of
TP53mutation observed in the CMgroup, when com-
pared to the ESCC/CM and ESCC (Table 3). We fur-
ther compared the distribution of TP53 mutations by
different exons in the three groups (Table 3). In the two
TP53 mutations in chagasic megaesophagus 5
Fig. 1 Electropherogram of TP53 gene. (A) TP53 wild-type sequence. (B) TP53mutant (His179Tyr) sequence. A, adenine; C, cytosine; G,
guanine; His, histidine; T, thymine, Tyr, tyrosine; Y, C and T.
Table 3 Association between frequency, exon distribution, nature and type of TP53 mutations in the three groups of patients
Groups (N = 105 cases)
ESCC CM ESCC/CM
(N = 40) (N = 33) (N = 32) P-value
Wild-type 22 (55.0%) 32 (97.0%) 19 (59.4%)Frequency TP53 <0.001∗Mutant 18 (45.0%) 1 (3.0%) 13 (40.6%)
Wild-type 36 (90.0%) 33 (100.0%) 27 (84.4%)5 0.037∗∗Mutant 4 (10.0%) 0 (0.0%) 5 (15.6%)
Wild-type 38 (95.0%) 32 (97.0%) 29 (90.6%)6 0.584∗∗Mutant 2 (5.0%) 1 (3.0%) 3 (9.4%)Exons
Wild-type 38 (95.0%) 33 (100.0%) 30 (93.8%)7 0.463∗∗Mutant 2 (5.0%) 0 (0.0%) 2 (6.2%)
Wild-type 30 (75.0%) 33 (100.0%) 27 (84.4%)8 0.003∗∗Mutant 10 (25.0%) 0 (0.0%) 5 (15.6%)
Absent 25 (60.0%) 32 (97.0%) 22 (65.6%)Missense 0.001∗Present 15 (40.0%) 1 (3.0%) 10 (34.4%)
Absent 38 (97.5%) 33 (100.0%) 30 (96.9%)Nature of mutations Nonsense 0.758∗∗Present 2 (2.5%) 0 (0.0%) 2 (3.1%)
Absent 39 (97.5%) 33 (100.0%) 29 (90.6%)Frameshift 0.147∗∗Present 1 (2.5%) 0 (0.0%) 3 (9.4%)
∗Chi-square test.
∗∗Fisher’s exact test.
CM, chagasic megaesophagus; ESCC, squamous cell carcinoma of the esophagus; ESCC/CM, squamous cell carcinoma of the esophagus
associated with chagasic megaesophagus; N, number of cases.
groups of patients suffering from cancer (ESCC/CM
and ESCC), mutations occurred in all 4 exons and
in the CM group, the only mutation observed was
on exon 5 (Table 3). In the ESCC/CM group and
ESCC exons 5 and 8 were equally affected (15.6% and
10% respectively). Regarding the nature of the muta-
tions, missense mutations were the most prevalent in
all three groups (Table 3).
Moreover, the correlation of TP53mutation profile
with patients clinical–pathological features indicates
the absence of any significant association (Table 4).
We also compared the overall survival curves between
TP53 mutated (red colour) and wild-type (blue
colour) patients in each group and no significant dif-
ferences (P = 0.175) were reported (Fig. 2).
In order to evaluate the potential carcinogenic
fingerprinting of each patient group, we considered
all nonsynonymous and synonymous (silent) muta-
tions (Table 5 and Fig. 3). We observed that in the
ESCC group, the most frequent type of mutation
was G:C→A:T in the CpG (31.8%), followed by
G:C→A:T non CpG (27.4%) andG:C→T:A (22.3%).
In group ESCC/CM, the most frequent mutation was
A:T→T:A (25%) and G:C→T:A (25%), followed by
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Fig. 2 Cumulative survival associated with the TP53 gene status. (A) ESCC, squamous cell carcinoma of the esophagus; (B) CM, chagasic
megaesophagus; (C) ESCC/CM, squamous cell carcinoma of the esophagus associated with chagasic megaesophagus.
Table 5 Frequency of the mutation type of TP53 in exons 5, 6, 7, and 8 (nonsynonymous and synonymous included)
Groups (N = 105 cases)
ESCC (N = 40) CM (N = 33) ESCC/CM (N = 32)
N mut = 22 N mut = 6 N mut = 16
A:T→C:G 0 (0.0%) 0 (0.0%) 0 (0.0%)
A:T→G:C 2 (9.1%) 0 (0.0%) 1 (6.2%)
A:T→T:A 1 (4.5%) 0 (0.0%) 4 (25.0%)
G:C→A:T 6 (27.4%) 6 (100.0%) 2 (12.5%)Mutation type G:C→A:T (CpG) 7 (31.8%) 0 (0.0%) 2 (12.5%)
G:C→C:G 0 (0.0%) 0 (0.0%) 0 (0.0%)
G:C→T:A 5 (22.3%) 0 (0.0%) 4 (25.0%)
Deletion 1 (4.5%) 0 (0.0%) 3 (18.8%)
CM, chagasic megaesophagus; ESCC, squamous cell carcinoma of the esophagus; ESCC/CM, squamous cell carcinoma of the esophagus
associated with chagasic megaesophagus, Mut, mutant; N, number of cases.
Fig. 3 Frequency distribution of fingerprinting profile. A, adenine;
C, cytosine; CM, chagasic megaesophagus; ESCC, squamous cell
carcinoma of the esophagus; ESCC/CM, squamous cell carcinoma
of the esophagus associated with chagasic megaesophagus; G, gua-
nine, T. thymine.
deletions (18.8%). In the CM group, all six mutations
identified (1 nonsynonimous and 5 synonimous) were
G:C→A:T non CpG (100%) (Table 5 and Fig. 3).
DISCUSSION
Chagasic megaesophagus (CM), a complication of
Chagas disease, is considered a predisposition condi-
tion for the development of ESCC.8,19,20 Despite this
known association, the molecular mechanisms under-
lying ESCC development in patients with CM are
unexplored. Such studies are of particular relevance
for Latin America and Brazil, where the Chagas dis-
ease is still endemic in some regions and represents an
important health problem.15
Herein, we investigate for the first time the pro-
file of TP53 mutation in ESCC associated with CM
(ESCC/CM) and compare it with the molecular pro-
file of ESCC not associated with megaesophagus and
with the benign CM. We showed that 40.6% of the
ESCC that develop in the context of CM harbor
TP53 mutations, which was similar to the ESCC
group (45%) and statistically superior to CM group
(3%). The high frequency of TP53 mutations in the
ESCC/CM group suggests that TP53 is also a key
player in tumorigenesis of ESCC in the context of
Chagas disease, as it has been widely accepted for
ESCC.24 The presence of TP53 mutation in CM
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patients, albeit at a significant lower frequency, may
mean that the TP53 mutation occurs already in pre-
malignant lesions. Interestingly, a previous study ana-
lyzed a series of CM, also from the same region
of the present study, for the presence of genomic
imbalances in genes relevant in esophageal carcino-
genesis, and any significant event was observed.22
So, TP53 mutations in the conjugation other etiolog-
ical factors may contribute to cancer development.
In fact, our observation of a higher consumption
of alcohol and tobacco observed in the ESCC/CM
group in comparison with the CM group, sup-
ported this hypothesis. Nevertheless, further studies,
using prospective epidemiological and case-control
designed approaches and involving a higher number
of patients are warranted to clarify this issue. We
observed slightly higher frequency (40.6%) of TP53
mutations in the ESCC without CM group, than pre-
vious published for Southern (34.8%) and Southeast
(34.5%) Brazilian population,25,28 and relatively lower
then what reported for countries with high incidence
of ESCC, such as China (42%–77%) and Iran (50%–
90%).29,30 These differences in ESCC TP53 mutation
frequencies observed worldwide may be associated
with multiple factors, including different exposure
agents, different population and different methodolo-
gies issues.
The TP53 gene is frequently mutated in human
tumors.23 The majority of these mutations are mis-
sense and occur between exons 5–8 leading to a func-
tional inactivation of cellular protein.23 According to
the IARC TP53mutation database, the hotspotsTP53
codons in ESCC of the esophagus are 170, 175,
179, 193, 220, 245, 248, 273, and 282.31 Most muta-
tions identified in our cases were in codons 151 and
275 (with three mutations each codon), followed by
codons 195, 196, 248, 273, 282, and 285 (with two
mutations each codon). Although is not usually con-
sidered to be a hotspot codon, mutation at position
151 leads to a structural alteration, which results in
significant functional changes in the p53 protein that
impact tumor progression.32 Although codon 275 is
not common referred to as hotspot mutations, the
Cys275Phe found in our cases is reported as a dele-
terious somatic mutation that leads to loss of protein
function.31
Besides the biological consequence, the analysis of
TP53mutations allows interrogating about the poten-
tial carcinogenic agent who operated in each case,
and therefore to understand the biological mecha-
nisms that drive inmalignant transformation. In other
words, the mutation spectrum analysis can function
as a molecular fingerprint of the agent that causes
DNA damage.33 The results of this study showed
that the most frequent type of mutation in the ESCC
group was G:C→A:T (CpG) (31.8%), followed by
G:C→A:T at non CpG sites (27.4%) and G:C→T:A
(22,3%). The transversion G:C→T:A mutations have
been frequently detected in lung tumors from heavy
smokers and experimentally associated with DNA
adduct formation by B[a]P metabolites.34,35 The
G:C→A:T transitions at non CpG sites are associ-
ated with both acetaldehyde and nitrosamines,34 so
there is a concordance between the identified risk fac-
tors (alcohol and tobacco). This type of mutations is
the most frequently described in CE.36 In CM group,
mutation type observed in all cases was a G:C→A:T,
as described above associated with acetaldehyde and
nitrosamines.34 These latter agents are important
compounds derived from food stasis observed inside
the megaesophagus.37 Finally, the most prevalent
mutations in the group ESCC/CM are G:C→T:A and
A:T→T:A, being the mutation G:C→T:A associated
with benzopyrene (tobacco)34,35 and the A:T→T:A
mutation are associated with acetaldehyde.38 The high
prevalence rates of these mutations in ESCC/CM
patients, further suggests that smoking and alcohol
are important cofactors for the development of ESCC
in patients with CM.
In conclusion, we observed a high frequency of
TP53 mutation in ESCC/CM, suggesting the central
role of TP53 the development of this unknown and
neglected tumor. Future studies will be important
to validate and extend these important findings that
may contribute to the elucidation of the carcinogenic
pathway of ESCC associated with chagasic megae-
sophagus.
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